Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours-evaluation of a potentially effective clinical therapy
1996

Using a modified herpes virus to treat brain tumors

Sample size: 9 publication Evidence: moderate

Author Information

Author(s): EA McKie, AR MacLean, AD Lewis, G Cruickshank, R Rampling, SC Barnett, PGE Kennedy, SM Brown

Primary Institution: Glasgow University

Hypothesis

Can the herpes simplex virus mutant 1716 effectively replicate in and kill primary human CNS tumors?

Conclusion

The HSV-1 mutant 1716 shows potential as a therapy for primary brain tumors by selectively replicating in tumor cells and causing cell death.

Supporting Evidence

  • HSV-1 mutant 1716 can replicate in most glioma cell lines tested.
  • 1716 causes cell death in glioma cells through selective replication.
  • Normal human brain tissue was not available for comparative analysis.

Takeaway

Researchers are testing a special virus that can kill brain tumor cells without harming normal cells, which could help treat brain cancer.

Methodology

The study evaluated the replication of HSV-1 mutant 1716 in established human glioma cell lines and primary cell cultures from tumor biopsies.

Limitations

The study was limited by the inability to establish and grow sufficient normal human brain tissue for comparison.

Participant Demographics

Patients with anaplastic astrocytoma or glioblastoma multiforme.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication